{"id":"NCT02277743","sponsor":"Regeneron Pharmaceuticals","briefTitle":"Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis","officialTitle":"A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-10","primaryCompletion":"2015-11","completion":"2016-02","firstPosted":"2014-10-29","resultsPosted":"2017-11-21","lastUpdate":"2017-11-21"},"enrollment":671,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Dermatitis, Atopic"],"interventions":[{"type":"DRUG","name":"Dupilumab","otherNames":["REGN668","SAR231893","DUPIXENT®"]},{"type":"DRUG","name":"Placebo (for Dupilumab)","otherNames":[]}],"arms":[{"label":"Placebo","type":"EXPERIMENTAL"},{"label":"Dupilumab 300 mg once weekly (qw)","type":"EXPERIMENTAL"},{"label":"Dupilumab 300 mg every 2 weeks (q2w)","type":"EXPERIMENTAL"}],"summary":"This is a randomized, double-blind, placebo-controlled, parallel group study to confirm the efficacy and safety of Dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis (AD).","primaryOutcome":{"measure":"Percentage of Participants With Investigator's Global Assessment (IGA) Score of \"0\" or \"1\" and Reduction From Baseline of ≥2 Points at Week 16","timeFrame":"Week 16","effectByArm":[{"arm":"Placebo","deltaMin":10.3,"sd":null},{"arm":"Dupilumab 300 mg q2w","deltaMin":37.9,"sd":null},{"arm":"Dupilumab 300 mg qw","deltaMin":37.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.0001"},{"comp":"OG000 vs OG002","p":"< 0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":101,"countries":["United States","Bulgaria","Canada","Denmark","Estonia","Finland","Germany","Japan","Singapore","Spain"]},"refs":{"pmids":["27690741","39588375","36808602","36723913","36269503","35636689","34897582","34726270","34142350","34037993","33453450","33165005","31424712","31407311","31066001","30791102","28503712"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":222},"commonTop":["Dermatitis atopic","Nasopharyngitis","Injection site reaction","Headache","Upper respiratory tract infection"]}}